Aliases & Classifications for Oligohydramnios

MalaCards integrated aliases for Oligohydramnios:

Name: Oligohydramnios 12 29 55 6 44 15 73
Oligohydramnios - Delivered 12 73
Oligohydramnios, Antepartum Condition or Complication 73
Antepartum Oligohydramnios 12
Delivered Oligohydramnios 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12215
ICD10 33 O41.0 O41.00
ICD9CM 35 658.0
MeSH 44 D016104
NCIt 50 C92839
SNOMED-CT 68 59566000

Summaries for Oligohydramnios

Disease Ontology : 12 A placenta disease that is characterized by a deficiency of amniotic fluid sometimes resulting in an embryonic defect through adherence between embryo and amnion.

MalaCards based summary : Oligohydramnios, also known as oligohydramnios - delivered, is related to potter's syndrome and renal tubular dysgenesis, and has symptoms including morning sickness An important gene associated with Oligohydramnios is PKHD1 (PKHD1, Fibrocystin/Polyductin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Postsynaptic nicotinic acetylcholine receptors. The drugs Warfarin and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include lung, placenta and heart, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 76 Oligohydramnios is a condition in pregnancy characterized by a deficiency of amniotic fluid. It is the... more...

Related Diseases for Oligohydramnios

Diseases related to Oligohydramnios via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 150)
# Related Disease Score Top Affiliating Genes
1 potter's syndrome 33.5 AGT REN
2 renal tubular dysgenesis 32.6 ACE AGT AGTR1 REN
3 multiple pterygium syndrome, lethal type 31.8 CHRNA1 CHRND CHRNG
4 polyhydramnios 30.9 AFP AQP1 AQP3
5 anuria 30.2 ACE AGT AGTR1 REN
6 renal dysplasia 30.2 ACE AGT AGTR1 REN
7 eclampsia 30.0 EDN1 OXT REN
8 fetal akinesia deformation sequence 30.0 CHRNA1 CHRND CHRNG
9 cystic lymphangioma 30.0 AFP CHRND CHRNG
10 pre-eclampsia 29.4 ADM AFP AGT AGTR1 EDN1 OXT
11 diabetes mellitus 29.3 ACE AGT AGTR1 EDN1 REN
12 kidney disease 29.0 ACE ADM AGT AGTR1 EDN1 NPPB
13 renal hypodysplasia/aplasia 1 11.3
14 twin-to-twin transfusion syndrome 11.3
15 bilateral renal agenesis dominant type 11.2
16 polycystic kidney disease 4 with or without polycystic liver disease 11.1
17 situs inversus totalis with cystic dysplasia of kidneys and pancreas 11.1
18 urethral obstruction sequence 11.1
19 congenital anomalies of kidney and urinary tract 2 11.0
20 meckel syndrome, type 1 11.0
21 renal dysplasia-limb defects syndrome 11.0
22 meckel syndrome, type 7 11.0
23 fetal indomethacin syndrome 11.0
24 trisomy 2 mosaicism 11.0
25 preterm premature rupture of the membranes 10.3
26 hyporeninemic hypoaldosteronism 10.3 ACE REN
27 hypoaldosteronism 10.3 ACE REN
28 pediatric hypertension 10.3 ACE AGT
29 renal artery obstruction 10.3 ACE REN
30 hypertension, diastolic 10.2 ACE REN
31 slow-channel congenital myasthenic syndrome 10.2 CHRNA1 CHRND
32 posterior urethral valves 10.2 ACE AGT AGTR1
33 microvascular complications of diabetes 3 10.2 ACE AGT AGTR1
34 hypertensive encephalopathy 10.2 ACE REN
35 interstitial nephritis 10.2 ACE AGT REN
36 familial hypertension 10.2 AGT AGTR1 REN
37 obstructive nephropathy 10.2 ACE AGT REN
38 hypertensive retinopathy 10.2 ACE REN
39 multiple pterygium syndrome, escobar variant 10.2 CHRNA1 CHRND CHRNG
40 malignant hypertensive renal disease 10.2 EDN1 REN
41 cystic kidney disease 10.2 CC2D2A PKHD1 TMEM67
42 malignant renovascular hypertension 10.2 EDN1 REN
43 mitral valve disease 10.2 ACE AGT AGTR1
44 neonatal myasthenia gravis 10.2 AFP CHRNG
45 vesicoureteral reflux 1 10.2 AGT AGTR1 REN
46 iga glomerulonephritis 10.2 ACE AGTR1 REN
47 orthostatic proteinuria 10.2 ACE REN
48 end stage renal failure 10.2 ACE AGT AGTR1
49 otosclerosis 10.2 ACE AGT AGTR1
50 renal artery disease 10.2 ACE AGT AGTR1 REN

Graphical network of the top 20 diseases related to Oligohydramnios:



Diseases related to Oligohydramnios

Symptoms & Phenotypes for Oligohydramnios

UMLS symptoms related to Oligohydramnios:


morning sickness

MGI Mouse Phenotypes related to Oligohydramnios:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.27 ACE ADM AFP AGT AGTR1 AQP1
2 cardiovascular system MP:0005385 10.21 ACE ADM AGT AGTR1 AQP1 AQP3
3 growth/size/body region MP:0005378 10.18 ACE AGT AGTR1 AQP1 AQP3 CC2D2A
4 mortality/aging MP:0010768 10.16 ACE ADM AFP AGT AGTR1 AQP1
5 homeostasis/metabolism MP:0005376 10.1 ACE ADM AFP AGT AGTR1 AQP1
6 digestive/alimentary MP:0005381 9.95 AQP3 CC2D2A EDN1 OXT PKHD1 TMEM67
7 nervous system MP:0003631 9.93 AGT AGTR1 AQP1 CC2D2A CHRNA1 CHRNG
8 renal/urinary system MP:0005367 9.77 ACE ADM AGT AGTR1 AQP1 AQP3
9 reproductive system MP:0005389 9.28 ACE ADM AFP AGT AQP1 OPHN1

Drugs & Therapeutics for Oligohydramnios

Drugs for Oligohydramnios (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4 81-81-2 6691 54678486
2
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
3
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
4
Coumarin Experimental Phase 4 91-64-5 323
5 Tocotrienol Investigational Phase 4 6829-55-6
6 Anticoagulants Phase 4,Not Applicable
7 Vitamins Phase 4,Not Applicable
8 Coagulants Phase 4
9 Antioxidants Phase 4,Phase 2,Phase 3
10 Tocopherols Phase 4
11 Tocotrienols Phase 4
12 Omega 3 Fatty Acid Phase 4
13 Protective Agents Phase 4,Phase 2,Phase 3
14
Dinoprostone Approved Phase 3 363-24-6 5280360
15
Oxytocin Approved, Vet_approved Phase 3 50-56-6 439302 53477758
16
AT-101 Approved, Investigational Phase 2, Phase 3 90141-22-3, 652-67-5 12597
17
Nitric Oxide Approved Phase 2, Phase 3 10102-43-9 145068
18
Isosorbide Dinitrate Approved, Investigational Phase 2, Phase 3 87-33-2 6883
19 Oxytocics Phase 3,Not Applicable
20 Vasodilator Agents Phase 2, Phase 3,Not Applicable
21 Endothelium-Dependent Relaxing Factors Phase 2, Phase 3
22 Neurotransmitter Agents Phase 2, Phase 3
23 Anti-Asthmatic Agents Phase 2, Phase 3
24 isosorbide-5-mononitrate Phase 2, Phase 3
25 Free Radical Scavengers Phase 2, Phase 3
26 Peripheral Nervous System Agents Phase 2, Phase 3
27 Nitric Oxide Donors Phase 2, Phase 3
28 Respiratory System Agents Phase 2, Phase 3
29 Natriuretic Agents Phase 2, Phase 3
30 Bronchodilator Agents Phase 2, Phase 3
31 diuretics Phase 2, Phase 3
32 Autonomic Agents Phase 2, Phase 3
33 Vaccines Phase 2,Not Applicable
34
Misoprostol Approved Not Applicable 59122-46-2 5282381
35
Pertuzumab Approved 145040-37-5, 380610-27-5 2540
36
Adenosine Approved, Investigational 58-61-7 60961
37
Trastuzumab Approved, Investigational 180288-69-1 9903
38
Indomethacin Approved, Investigational 53-86-1 3715
39
Polyestradiol phosphate Approved 28014-46-2
40
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
41 Estradiol valerate Approved, Investigational, Vet_approved 979-32-8
42
Citric Acid Approved, Nutraceutical, Vet_approved Not Applicable 77-92-9 311
43
Ergocalciferol Approved, Nutraceutical Not Applicable 50-14-6 5280793
44
Vitamin D Approved, Nutraceutical, Vet_approved Not Applicable 1406-16-2
45
Vitamin D3 Approved, Nutraceutical Not Applicable 67-97-0 5280795 6221
46 Phosphodiesterase 5 Inhibitors Not Applicable
47 Chelating Agents Not Applicable
48 Calcium, Dietary Not Applicable
49 Citrate Not Applicable
50 Sildenafil Citrate Not Applicable 171599-83-0

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Warfarine in Unexplained Oligohydramnios Completed NCT01569035 Phase 4 warfarin
2 Role of Antioxidants in Unexplained Oligohydramnios,A Randomized Trial Completed NCT01990690 Phase 4 anti oxidant omega 3
3 Amnioinfusion Initiative Unknown status NCT00787163 Phase 3
4 Induction of Labor in Oligohydramnios Unknown status NCT00815542 Phase 3 prostaglandins E2
5 Stepwise Labor Induction Following Failure of Prostaglandin Vaginal Insert for Labor Induction Unknown status NCT02684305 Phase 3 Administration of Propess;Intravenous oxytocin infusion
6 Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses Unknown status NCT00127946 Phase 3
7 Nitric Oxide Donors for Treatment of Isolated Oligohydramnios Completed NCT02712125 Phase 2, Phase 3 isosorbide mononitrate;Placebo
8 Mechanical cervicAl ripeninG for Women With PrOlongedPregnancies Recruiting NCT02907060 Phase 3 Pharmacological cervical ripening
9 The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor Completed NCT00404768 Phase 2 GSK221149A;Placebo
10 A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers Withdrawn NCT03191383 Phase 2 Placebo (Formulation buffer S9b)
11 Alterations of the Uteroplacental and Fetal Pulmonary Circulation Following Amnioinfusion Unknown status NCT01258725 Phase 1
12 Fetal Renal Artery Doppler Indices in Borderline Isolated Oligohydramnios Unknown status NCT02901340
13 Sildenafil Citrate Therapy for Oligohydramnios Unknown status NCT02372487 Not Applicable sildenafil citrate
14 A Screening Strategy for Q Fever Among Pregnant Women Unknown status NCT01095328 Not Applicable
15 Vitamin D Treatment and Hypocalcemic Pregnant Women Unknown status NCT02021864 Not Applicable vitamin D3 50,000 unit;prenatal multivitamin
16 İs There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels? Unknown status NCT01906567
17 Active Induction of Labor in Pregnancies Complicated With Oligohydramnios at Term Completed NCT02581774
18 Studying Fetal Breathing Patterns Completed NCT00066976
19 Foley Catheter Versus Vaginal Misoprostol for Cervical Ripening and Induction of Labor Completed NCT01140971 Not Applicable Misoprostol
20 Coffee Consumption and Pregnancy Completed NCT03798275 Not Applicable
21 Perinatal Outcome After Premature Rupture of Membranes Completed NCT01538030
22 Functional Capacity After Computer Assisted Periacetabular Osteotomy in Patients With Hip Dysplasia Completed NCT02015247 Not Applicable
23 Determination of Abnormal Fetal Growth or Amniotic Fluid With Third Trimester Ultrasounds in Uncomplicated Pregnancies: A Randomized Trial Completed NCT02702999 Not Applicable
24 Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Congenital Diaphragm Hernia Completed NCT02596802 Not Applicable
25 Uterine, Fetal Cerebral Doppler and Oligohydramnios to Predict Abnormal Heart Rate Tracings in Postterm Pregnancies Recruiting NCT03703037
26 PPROM Registry (Preterm Premature Rupture of Membranes) Recruiting NCT02997345
27 Renal Agenesis Fetal Therapy Recruiting NCT03101891 Not Applicable Normal Saline, 0.9% injectable solution
28 Fetoscopic Endoluminal Tracheal Occlusion (FETO) Recruiting NCT03674372 Not Applicable
29 Third Trimester Modified Biophysical Profile Scan for Predicting Fetal Outcome. Recruiting NCT03729089 Not Applicable
30 Placenta Imaging Project Recruiting NCT02749851
31 Fetal Endotracheal Occlusion (FETO) in Severe and Extremely Severe Congenital Diaphragmatic Hernia Recruiting NCT00881660 Not Applicable
32 A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine Recruiting NCT00833963 Trastuzumab;Pertuzumab;Ado-Trastuzumab Emtansine
33 Fitbit Activity Tracker to Predict Risk of Preterm Birth Recruiting NCT03304782
34 Fetal Endoscopic Surgery for Spina Bifida Recruiting NCT03315637 Not Applicable
35 Indomethacin PK and PD Therapy in Pregnancy Active, not recruiting NCT02451228
36 Systemic Lupus and Adverse Pregnancy Outcome Enrolling by invitation NCT03171103
37 Diabetes Mellitus With Pregnancy in Benisuef Localities Enrolling by invitation NCT03169205
38 Low Sodium Diet in Oligohydramnios Assigned for Conservative Management Not yet recruiting NCT03815968 Not Applicable
39 Does Amniotic Fluid Index Affect the Fetal Cardiac Performance? Not yet recruiting NCT03277417
40 A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance Not yet recruiting NCT03614676 Not Applicable
41 Maternal- Fetal Infection Not yet recruiting NCT03371056 Not Applicable
42 Hydrotherapy for the Reversal of Oligohydramnios Terminated NCT01682928 Not Applicable IV/Oral Hydration and Bedrest

Search NIH Clinical Center for Oligohydramnios

Cochrane evidence based reviews: oligohydramnios

Genetic Tests for Oligohydramnios

Genetic tests related to Oligohydramnios:

# Genetic test Affiliating Genes
1 Oligohydramnios 29

Anatomical Context for Oligohydramnios

MalaCards organs/tissues related to Oligohydramnios:

41
Lung, Placenta, Heart, Kidney, Fetal Lung, Liver, Pancreas

Publications for Oligohydramnios

Articles related to Oligohydramnios:

(show top 50) (show all 485)
# Title Authors Year
1
Outcomes in oligohydramnios: the role of etiology in predicting pulmonary morbidity/mortality. ( 29924737 )
2018
2
Induction of labor in cases of late preterm isolated oligohydramnios: is it justified? ( 29343146 )
2018
3
Is pregnancy associated plasma protein-A (PAPP-A) a marker for adverse perinatal outcomes in preterm isolated oligohydramnios cases? ( 29458908 )
2018
4
Survival Rate without Brain Abnormalities on Postnatal Ultrasonography among Monochorionic Twins after Fetoscopic Laser Photocoagulation for Selective Intrauterine Growth Restriction with Concomitant Oligohydramnios. ( 29462812 )
2018
5
Diabetes Insipidus Presenting with Oligohydramnios and Polyuria During Pregnancy. ( 30135348 )
2018
6
Amnioinfusion for variable decelerations caused by umbilical cord compression without oligohydramnios but with the sandwich sign as an early marker of deterioration. ( 30246578 )
2018
7
Effect of Oligohydramnios on Fetal Heart Rate Patterns during Term Labor Induction. ( 30372774 )
2018
8
Maternal and perinatal outcomes of induction of labor in oligohydramnios at term - a retrospective cohort study. ( 30394156 )
2018
9
Delivery mode and perinatal outcomes after diagnosis of oligohydramnios at term in China. ( 30486718 )
2018
10
Oligohydramnios compromises lung cells size and interferes with epithelial-endothelial development. ( 28152278 )
2017
11
Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. ( 28277352 )
2017
12
Perinatal outcomes in uncomplicated late preterm pregnancies with borderline oligohydramnios. ( 28782398 )
2017
13
Prenatal parental decision-making and postnatal outcome in renal oligohydramnios. ( 29075889 )
2017
14
A case of gestational central diabetes insipidus with oligohydramnios. ( 28764595 )
2017
15
Inhaled Nitric Oxide in preterm Neonates with refractory hypoxemia associated to oligohydramnios. ( 29046161 )
2017
16
Oligohydramnios is an independent risk factor for perinatal morbidity among women with pre-eclampsia who delivered preterm. ( 29237307 )
2017
17
Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. ( 28644321 )
2017
18
MRI findings of chronic abruption-oligohydramnios sequence (CAOS): report of three cases. ( 28396921 )
2017
19
Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. ( 29064958 )
2017
20
Midtrimester isolated oligohydramnios in monochorionic diamniotic multiple gestations<sup/>. ( 28965437 )
2017
21
Evaluation of Maternal and Perinatal Outcomes of Induction in Borderline Oligohydramnios at Term. ( 29207783 )
2017
22
Report of a Triploid Fetus Identified in a Pregnancy with Oligohydramnios. ( 28459702 )
2017
23
Pregnancy Outcomes in Isolated Oligohydramnios during Second Trimester: A Case Series. ( 28969220 )
2017
24
Causes of renal oligohydramnios: impact on prenatal counseling and postnatal outcome. ( 29128922 )
2017
25
Pulmonary Hypoplasia Induced by Oligohydramnios: Findings from Animal Models and a Population-Based Study. ( 27324123 )
2016
26
EP16.18: Outcome of the patients with late second trimester isolated oligohydramnios and echogenic bowel without evidence of premature rupture membranes. ( 27644197 )
2016
27
Induction of Labor in Women with Oligohydramnios: Misoprostol Compared with Prostaglandin E2. ( 27398704 )
2016
28
Sildenafil citrate for the management of fetal growth restriction and oligohydramnios. ( 27563258 )
2016
29
Survival of fetuses with severe oligohydramnios. ( 27328487 )
2016
30
Role of l-Arginine in Oligohydramnios. ( 27651617 )
2016
31
Isolated Oligohydramnios at Term as an Indication for Labor Induction: A Systematic Review and Meta-Analysis. ( 27160748 )
2016
32
Oligohydramnios and growth restriction do not portend worse prognosis in gastroschisis pregnancies. ( 26932657 )
2016
33
Use of an Amnioport to Maintain Amniotic Fluid Volume in Fetuses with Oligohydramnios Secondary to Lower Urinary Tract Obstruction or Fetal Renal Anomalies. ( 27287190 )
2016
34
Are Major Depression and Generalized Anxiety Disorder Associated With Oligohydramnios in Pregnant Women? A Case-Control Study. ( 27357862 )
2016
35
Prostaglandin E2 induction of labor and cervical ripening for term isolated oligohydramnios in pregnant women with Bishop scoreA a8oA 5. ( 27745800 )
2016
36
A randomized controlled study of the efficacy of 4 weeks of supplementation with I8-3 polyunsaturated fatty acids in cases of unexplained oligohydramnios. ( 27559716 )
2016
37
Aquaporin 3 Expression Induced by Salvia Miltiorrhiza via ERK1/2 Signal Pathway in the Primary Human Amnion Epithelium Cells from Isolated Oligohydramnios. ( 26917259 )
2016
38
Lack of pharmacist-physician communication associated with nimesulide-induced oligohydramnios during pregnancy. ( 26951121 )
2016
39
Oligohydramnios in complicated and uncomplicated pregnancies: a systematic review and meta-analysis. ( 27062200 )
2016
40
Obstetric outcomes of isolated oligohydramnios during early-term, full-term and late-term periods and determination of optimal timing of delivery. ( 27225520 )
2016
41
Significance of oligohydramnios in preterm small-for-gestational-age infants for outcome at 18 months of age. ( 27352940 )
2016
42
Perinatal outcomes with isolated oligohydramnios at term pregnancy. ( 26506098 )
2015
43
Feasibility and preliminary outcomes of fetoscopic laser photocoagulation for monochorionic twin gestation with selective intrauterine growth restriction accompanied by severe oligohydramnios. ( 26369752 )
2015
44
Placental lesions associated with oligohydramnios in fetal growth restricted (FGR) pregnancies. ( 25735841 )
2015
45
What does fetal autopsy unmask in oligohydramnios? ( 26381033 )
2015
46
Outcomes and management strategies in pregnancies with early onset oligohydramnios. ( 26152010 )
2015
47
Short-Term and Long-Term Postnatal Outcomes of Expectant Management After Previable Preterm Premature Rupture of Membranes With and Without Persistent Oligohydramnios. ( 26444125 )
2015
48
Important clinical information from successful treatment of a case with isolated severe oligohydramnios and deficient fetal growth late in the second trimester. ( 26384073 )
2015
49
An Update on Maternal Hydration Strategies for Amniotic Fluid Improvement in Isolated Oligohydramnios and Normohydramnios: Evidence from a Systematic Review of Literature and Meta-Analysis. ( 26658482 )
2015
50
Reversible oligohydramnios in the second trimester of pregnancy in two patients with long-term diclofenac exposure. ( 26318712 )
2015

Variations for Oligohydramnios

ClinVar genetic disease variations for Oligohydramnios:

6 (show all 16)
# Gene Variation Type Significance SNP ID Assembly Location
1 TMEM67 NM_153704.5(TMEM67): c.1843T> C (p.Cys615Arg) single nucleotide variant Pathogenic/Likely pathogenic rs201893408 GRCh37 Chromosome 8, 94808198: 94808198
2 TMEM67 NM_153704.5(TMEM67): c.1843T> C (p.Cys615Arg) single nucleotide variant Pathogenic/Likely pathogenic rs201893408 GRCh38 Chromosome 8, 93795970: 93795970
3 PKHD1 NM_138694.3(PKHD1): c.107C> T (p.Thr36Met) single nucleotide variant Pathogenic rs137852944 GRCh37 Chromosome 6, 51947999: 51947999
4 PKHD1 NM_138694.3(PKHD1): c.107C> T (p.Thr36Met) single nucleotide variant Pathogenic rs137852944 GRCh38 Chromosome 6, 52083201: 52083201
5 CC2D2A NM_001080522.2(CC2D2A): c.4179+1delG (p.Gly1394Valfs) deletion Pathogenic rs386833760 GRCh37 Chromosome 4, 15589553: 15589553
6 CC2D2A NM_001080522.2(CC2D2A): c.4179+1delG (p.Gly1394Valfs) deletion Pathogenic rs386833760 GRCh38 Chromosome 4, 15587930: 15587930
7 TMEM67 NM_153704.5(TMEM67): c.1321C> T (p.Arg441Cys) single nucleotide variant Pathogenic/Likely pathogenic rs752362727 GRCh38 Chromosome 8, 93786255: 93786255
8 TMEM67 NM_153704.5(TMEM67): c.1321C> T (p.Arg441Cys) single nucleotide variant Pathogenic/Likely pathogenic rs752362727 GRCh37 Chromosome 8, 94798483: 94798483
9 PKHD1 NM_138694.3(PKHD1): c.2716-3C> G single nucleotide variant Uncertain significance rs1057518964 GRCh37 Chromosome 6, 51908531: 51908531
10 PKHD1 NM_138694.3(PKHD1): c.2716-3C> G single nucleotide variant Uncertain significance rs1057518964 GRCh38 Chromosome 6, 52043733: 52043733
11 OPHN1 NM_002547.2(OPHN1): c.746T> C (p.Leu249Pro) single nucleotide variant Likely pathogenic rs1057518963 GRCh37 Chromosome X, 67430081: 67430081
12 OPHN1 NM_002547.2(OPHN1): c.746T> C (p.Leu249Pro) single nucleotide variant Likely pathogenic rs1057518963 GRCh38 Chromosome X, 68210239: 68210239
13 CC2D2A NM_001080522.2(CC2D2A): c.1149+1G> A single nucleotide variant Pathogenic GRCh37 Chromosome 4, 15518380: 15518380
14 CC2D2A NM_001080522.2(CC2D2A): c.1149+1G> A single nucleotide variant Pathogenic GRCh38 Chromosome 4, 15516757: 15516757
15 INF2 NM_022489.3(INF2): c.3247A> G (p.Ser1083Gly) single nucleotide variant Uncertain significance GRCh38 Chromosome 14, 104714409: 104714409
16 INF2 NM_022489.3(INF2): c.3247A> G (p.Ser1083Gly) single nucleotide variant Uncertain significance GRCh37 Chromosome 14, 105180746: 105180746

Expression for Oligohydramnios

Search GEO for disease gene expression data for Oligohydramnios.

Pathways for Oligohydramnios

GO Terms for Oligohydramnios

Cellular components related to Oligohydramnios according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 ACE ADM AFP AGT EDN1 NPPB
2 MKS complex GO:0036038 9.16 CC2D2A TMEM67
3 acetylcholine-gated channel complex GO:0005892 8.8 CHRNA1 CHRND CHRNG
4 plasma membrane GO:0005886 10.03 ACE AGTR1 AQP1 AQP3 CHRNA1 CHRND

Biological processes related to Oligohydramnios according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.98 AQP1 CHRNA1 CHRND CHRNG
2 cell surface receptor signaling pathway GO:0007166 9.97 AGT EDN1 GPR182 NPPB
3 heart development GO:0007507 9.96 ADM CC2D2A EDN1 OXT
4 cellular response to hypoxia GO:0071456 9.87 AQP1 AQP3 EDN1
5 regulation of membrane potential GO:0042391 9.87 CHRNA1 CHRND CHRNG
6 female pregnancy GO:0007565 9.86 ADM AGT OXT
7 positive regulation of cytosolic calcium ion concentration GO:0007204 9.83 ADM AGT AGTR1 EDN1 OXT
8 excitatory postsynaptic potential GO:0060079 9.81 CHRNA1 CHRND CHRNG
9 nervous system process GO:0050877 9.78 CHRNA1 CHRND CHRNG
10 regulation of postsynaptic membrane potential GO:0060078 9.77 CHRNA1 CHRND CHRNG
11 kidney development GO:0001822 9.77 ACE AGT AGTR1 PKHD1 REN
12 neuromuscular synaptic transmission GO:0007274 9.71 CHRNA1 CHRND CHRNG
13 response to nicotine GO:0035094 9.71 CHRNA1 CHRND CHRNG EDN1
14 water transport GO:0006833 9.69 AQP1 AQP3
15 positive regulation of cellular protein metabolic process GO:0032270 9.69 AGT AGTR1
16 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.69 AGT AGTR1
17 synaptic transmission, cholinergic GO:0007271 9.69 CHRNA1 CHRND CHRNG
18 vasoconstriction GO:0042310 9.68 AGT EDN1
19 amyloid-beta metabolic process GO:0050435 9.68 ACE REN
20 low-density lipoprotein particle remodeling GO:0034374 9.67 AGT AGTR1
21 positive regulation of urine volume GO:0035810 9.67 EDN1 NPPB
22 positive regulation of blood pressure GO:0045777 9.67 ACE AGT OXT
23 angiotensin maturation GO:0002003 9.66 ACE REN
24 artery smooth muscle contraction GO:0014824 9.65 AGT EDN1
25 body fluid secretion GO:0007589 9.65 EDN1 NPPB
26 regulation of blood vessel size GO:0050880 9.65 AGT EDN1 NPPB
27 positive regulation of cholesterol esterification GO:0010873 9.64 AGT AGTR1
28 drinking behavior GO:0042756 9.63 OXT REN
29 regulation of blood vessel diameter GO:0097746 9.63 ACE AGTR1 NPPB
30 glycerol transport GO:0015793 9.62 AQP1 AQP3
31 positive regulation of NAD(P)H oxidase activity GO:0033864 9.62 AGT AGTR1
32 positive regulation of prostaglandin secretion GO:0032308 9.61 EDN1 OXT
33 musculoskeletal movement GO:0050881 9.59 CHRNA1 CHRND
34 regulation of renal sodium excretion GO:0035813 9.58 AGT AGTR1
35 nitric oxide transport GO:0030185 9.58 AQP1 EDN1
36 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.57 AGT AGTR1
37 regulation of blood volume by renin-angiotensin GO:0002016 9.56 AGT REN
38 skeletal muscle tissue growth GO:0048630 9.55 CHRNA1 CHRND
39 regulation of renal output by angiotensin GO:0002019 9.52 ACE AGT
40 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.5 ACE AGT AGTR1
41 regulation of vasoconstriction GO:0019229 9.46 ACE AGT AGTR1 EDN1
42 renin-angiotensin regulation of aldosterone production GO:0002018 9.43 AGT AGTR1 REN
43 regulation of blood pressure GO:0008217 9.35 ACE AGT EDN1 NPPB REN
44 positive regulation of renal sodium excretion GO:0035815 8.92 AGT EDN1 NPPB OXT
45 signal transduction GO:0007165 10.26 ADM AGTR1 CHRNA1 CHRND CHRNG GPR182
46 regulation of signaling receptor activity GO:0010469 10.03 ADM AGT EDN1 NPPB OXT

Molecular functions related to Oligohydramnios according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular ligand-gated ion channel activity GO:0005230 9.61 CHRNA1 CHRND CHRNG
2 ligand-gated ion channel activity GO:0015276 9.58 CHRNA1 CHRND CHRNG
3 channel activity GO:0015267 9.54 AQP1 AQP3 CHRNG
4 water channel activity GO:0015250 9.46 AQP1 AQP3
5 acetylcholine binding GO:0042166 9.43 CHRNA1 CHRND CHRNG
6 acetylcholine-gated cation-selective channel activity GO:0022848 9.33 CHRNA1 CHRND CHRNG
7 bradykinin receptor binding GO:0031711 9.32 ACE AGTR1
8 acetylcholine receptor activity GO:0015464 9.13 CHRNA1 CHRND CHRNG
9 hormone activity GO:0005179 9.02 ADM AGT EDN1 NPPB OXT

Sources for Oligohydramnios

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....